Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF10B, CS-1008(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6311MR)

This product GTTS-WQ6311MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets TNFRSF10B gene. The antibody can be applied in Solid tumors, research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_003842.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 8795
UniProt ID O14763
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF10B, CS-1008(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ6311MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4831MR IVTScrip™ mRNA-Anti-CD4, BT-061(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BT-061
GTTS-WQ11506MR IVTScrip™ mRNA-Anti-MET, MetMAb(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MetMAb
GTTS-WQ2963MR IVTScrip™ mRNA-Anti-IL33, ANB020(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ANB020
GTTS-WQ11193MR IVTScrip™ mRNA-Anti-TNFRSF4, MEDI0562(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MEDI0562
GTTS-WQ6804MR IVTScrip™ mRNA-Anti-STEAP1, DSTP-3086S(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA DSTP-3086S
GTTS-WQ11515MR IVTScrip™ mRNA-Anti-FGFR3, MFGR1877S(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MFGR1877S
GTTS-WQ5795MR IVTScrip™ mRNA-Anti-CD40, CFZ-533(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CFZ-533
GTTS-WQ5888MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, CIFN(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CIFN
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW